Prostate cancer · 8 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Abiraterone and Niraparib Variant #01 | BRCA | R 78 430 | 28d | — | — | — | — | — |
Olaparib monotherapy Variant #01 | BRCA | R 59 224 | 28d | — | 19.1 mo | — | — | 1 |
Enzalutamide monotherapy Variant #01 | BRCA | R 14 528 | 28d | 4.2 mo | 17.5 mo | 5 | R 72 642 PFS proxy | 13 |
Abiraterone monotherapy Variant #01 | BRCA | R 10 334 | 28d | 4.9 mo | 15.4 mo | 6 | R 62 006 PFS proxy | 9 |
Docetaxel and Prednisone Variant #01 | BRCA | R 4 155 | 42d | — | 21.2 mo | — | — | 13 |
Docetaxel and Prednisolone Variant #01 | BRCA | R 1 387 | 14d | 8.3 mo | 19.1 mo | 19 | R 26 352 PFS proxy | 3 |
Abiraterone and Niraparib (combined pill) Variant #01 Partial | BRCA | R 11 | 28d | — | — | — | — | — |
Rucaparib monotherapy Variant #01 Partial | BRCA | — | 28d | ~20.2 mo | ~27.7 mo | ~22 | — | 7 |
8 of 8 regimens shown